FDA Approves Imfinzi: Breakthrough for Stage III NSCLC Treatment
The FDA's approval of Imfinzi offers new hope for patients with Stage III non-small cell lung cancer (NSCLC), enhancing treatment possibilities.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 08, 2026
The U.S. Food and Drug Administration (FDA) granted **FDA Imfinzi approval** to AstraZeneca's Imfinzi (durvalumab) for the treatment of patients with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemoradiation therapy, marking a significant advancement in consolidative Immunotherapy for this patient population.
Drug Overview
Durvalumab (Imfinzi) is a human monoclonal antibody targeting PD-L1. It is indicated for patients with unresectable Stage III NSCLC whose disease has not progressed following platinum-based chemoradiation.
Clinical Insights
The durvalumab approval was based on the Phase 3 PACIFIC trial (NCT02125461), which assessed progression-free survival and overall survival. The trial demonstrated improved progression-free survival and overall survival in patients receiving durvalumab after chemoradiation. Common adverse events include immune-related events such as pneumonitis, colitis, hepatitis, and endocrinopathies, consistent with the PD-L1 inhibitor class.
Regulatory Context
The durvalumab approval followed the submission of a Biologics License Application (BLA). The review process included priority review designation due to the unmet medical need in unresectable Stage III NSCLC. Post-marketing commitments typically include ongoing safety monitoring and additional studies to further characterize long-term outcomes.
Market Impact
Durvalumab expands treatment options for approximately 30% of NSCLC patients diagnosed at Stage III who are unresectable. The approval shifted the standard of care from chemoradiation alone to consolidative immunotherapy. Competitive drugs include pembrolizumab and nivolumab, however, durvalumab has a distinct indication for unresectable Stage III NSCLC post-chemoradiation.
Future Outlook
Future outlook for durvalumab may include upcoming label expansions and combination trials.
Frequently Asked Questions
What is the mechanism of action of durvalumab?
Durvalumab is a human monoclonal antibody targeting PD-L1, blocking its interaction with PD-1 and CD80 to restore T-cell mediated anti-tumor immune response.
What were the key findings from the PACIFIC trial?
The PACIFIC Phase 3 trial demonstrated improved progression-free survival and overall survival in patients receiving durvalumab after chemoradiation for unresectable Stage III NSCLC.
What are the common adverse events associated with durvalumab?
Common adverse events include immune-related events such as pneumonitis, colitis, hepatitis, and endocrinopathies, consistent with the PD-L1 inhibitor class.
References
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-08.
Senior Medical Editor
Dr. Sarah Chen is a board-certified internist and former FDA clinical reviewer with 15+ years of experience in pharmaceutical regulatory affairs. She received her MD from Johns Hopkins and her PhD in ...
